Brief: Aravive Announces Enrollment In The Global Registrational Phase 3 Axlerate-OC Trial For Platinum-Resistant Ovarian Cancer

Aravive

04/01/2023 12:12

Jan 4 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES COMPLETE ENROLLMENT IN THE GLOBAL
REGISTRATIONAL PHASE 3 AXLERATE-OC TRIAL FOR PLATINUM-RESISTANT
OVARIAN CANCER
    * ARAVIVE INC - TOPLINE DATA EXPECTED MID-2023
    * ARAVIVE INC - POTENTIAL BIOLOGICS LICENSE APPLICATION
(BLA)
SUBMISSION END OF 2023

Source text for Eikon:  ID:nGNX46rWLZ 
Further company coverage:  ARAV.O 
 ((Reuters.Briefs@thomsonreuters.com;))